Day: August 21, 2025

HighlightsThe Hearing division delivered 8% organic revenue growth driven by broad-based market share gains of ReSound Vivia across global markets growing below structural trends. The strong growth led to 12% growth in divisional profit, equaling a divisional profit margin of 36% driven by operating leverage The Enterprise division was – as expected – challenged by market uncertainty due to the global trade environment. The organic revenue growth was -7% due to the market uncertainty and a difficult comparison base, while being supported by strong progress in FalCom. The divisional profit margin ended at 34% as a result of pricing discipline and cost focus, offsetting the direct tariff costs The Gaming division was – as expected – challenged by the tariff environment and weak consumer sentiment. Despite these challenges, Gaming performed...

Growth in the sea has been very good, paving the way for increased volume, with a higher share of superior quality fish, and positive cost development in the second half of the year. As expected, the second quarter was marked by weak price achievement due to a high proportion of downgraded fish, particularly in Central Norway. Operational EBIT for Norway was NOK 696 million in Q2 2025. The harvest volume was 54,500 tonnes, and operational EBIT per kg was NOK 12.8. Group operational EBIT was NOK 524 million in Q2 2025. The harvest volume was 64,500 tonnes, and the EBIT per kg was NOK 8.1. Strong biological performance from Northern Norway with positive cost development during the period. Very good results from Sales and Industry driven by positive contributions from contracts and capabilities in our set-up. SalMar Ocean completed harvest...

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results1 Group performance2: Reflects strategic investment for long-term value creationRevenue of $390.4 million, up by 63%3 and on track to meet full year guidance4. Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable. Adjusted EBITDA5 of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D) investment. $81.6 million invested into R&D, a 47% increase...